
Jason Ronald Fangusaro MD
Pediatric Neuro-Oncology
Director of Developmental Therapeutics Professor of Pediatrics Emory University School of Medicine, Aflac Cancer Center and the Children's Healthcare of Atlanta
Join to view full profile
2220 N Druid Hills RdAtlanta, GA 30329
Phone+1 404-785-7000
Fax+1 404-325-6166
Dr. Fangusaro is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jason Fangusaro is a Pediatric Neuro-Oncologist. He currently is the Director of Developmental Therapeutics at CHOA/Emory. Published in several high-impact journals, he has contributed to the field with numerous brain tumor clinical trials. He serves as the Co-Director of both RAPNO and the International Pediatric Low-grade Glioma Coalition, and he is the Vice Chair of the COG CNS committee.
Education & Training
Children's Hospital of Los AngelesFellowship, Pediatric Neuro-Oncology, 2005 - 2006
Nationwide Children's Hospital/Ohio State UniversityFellowship, Pediatric Hematology/Oncology, 2002 - 2005
Advocate Health Care/Advocate Children's Hospital (Park Ridge)Residency, Pediatrics, 1999 - 2002
Loyola University Chicago Stritch School of MedicineClass of 1999
Loyola University ChicagoB.A., Theatre Arts, 1991 - 1995
Certifications & Licensure
GA State Medical License 2018 - 2027
IL State Medical License 2001 - 2020
CA State Medical License 2005 - 2007
OH State Medical License 2001 - 2007
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- World's Top 2% Scientists Stanford University, 2023
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
- Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Start of enrollment: 2010 Jul 07
- AZD6244 in Children With Low-Grade Gliomas Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- The DIPG/DMG National Tumor Board: The power of advocacy.Rebecca Ronsley, Greta Peng, Eileen Gutierrez, Patricia Baxter, Jason Fangusaro
Neuro-Oncology Pediatrics. 2026-10-01 - Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.Holly B Lindsay, Catherine A Billups, Mehmet Kocak, Tyler J Alban, Tina Young Poussaint
Clinical Cancer Research. 2026-06-30 - Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.Chelsea Kotch, Sebastien Perreault, Phoebe Power, David J Adams, Kenneth Aldape
Neuro-Oncology. 2026-05-19
Journal Articles
- Prospective Feasibility and Safety of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine GliomaGupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Ge..., Neuro Oncol, 1/5/2018
- Phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC)Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S..., Neuro Oncol, 1/28/2017
- Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survivalMarinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al- Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fang..., 1/21/2017
Books/Book Chapters
Abstracts/Posters
- Outcomes of a Phase 2 trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System (CNS) Non-Germinomatous Germ Cell Tumors NGGCT): a C...Fangusaro J, Wu S, MacDonald S, Murphy E, Shaw D, Bartels U, Khatua S, Boyett J, Williams-Hughes C, Souweidane M, Lu H, Morris D, Panigrahy A, Onar-Thomas A, Fouladi M..., Neuro-Oncology, 1/1/2018
- A Phase II and Re-treatment Study of Selumetinib in Children with Recurrent/Progressive LGG: a Pediatric Brain Tumor Consortium StudyFangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn L, Pollack IF, Qaddoumi I, Fisher PG, Dhall G, Baxter P, Kreissman..., Neuro-Oncology, 1/1/2018
- A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG: A Pediatric Brain Tumor Consortium StudyFangusaro J,� Onar-Thomas A,� Young-Poussaint T,�Wu S, Ligon AH, Lindeman NI, Banerjee A,�Packer R,�Kilburn LB,�Pollack I,�Jakacki R,�Qaddoumi IA, Fisher PG, Dhall G,�..., Journal of Clini Oncology, 1/1/2017
Lectures
- A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.2019 ASCO Annual Meeting - 6/1/2019
- Targeting MAPK in Pediatric OncologyChicago, IL - 1/1/2018
- A Phase II and Re-treatment Study of Selumetinib in Children with Recurrent/Progressive LGG: a Pediatric Brain Tumor Consortium StudyDenver, CO - 1/1/2018
Other
- Selumetinib in children with recurrent or refractory low-grade gliomaASCO Interview
1/1/2017 - Pediatric Brain and Spinal Cord TumorsPediatric Neuro-Oncology: Ask the Experts
http://www.youtube.com/watch?v=LZ3ibm8-ZWo
1/1/2013
Press Mentions
Evolving Treatment Approaches in Pediatric Low-Grade GliomaApril 8th, 2025- ContentsFebruary 11th, 2021
Pediatric Brain Tumor Consortium Adds Members: Dana-Farber, the Hospital for Sick Children, Univ. Of Florida & Nationwide Children’s HospitalSeptember 2nd, 2020
Grant Support
- R50NIH/NCI2026–2031
Committees
- Co-leader, International Coalition on Pediatric LGG 2020 - Present
- Co-Chair, RAPNO 2020 - Present
- Member, COG CNS Steering Committee 2017 - Present
- Vice-Chair, PBTC Executice Committee 2016 - Present
- Member, International CNS GCT Committee 2013 - Present
Professional Memberships
- Society of Neuro-OncologyMember
- Pediatric Brain Tumor ConsortiumVice Chair
- Children's Oncology GroupMember
- Member
Other Languages
- Spanish
Industry Relationships
- Pediatric "Unbranded" Educational Speaker's Bureau, DAY ONEEducational Talks that are focused on Pediatric Low-Grade Glioma (Unbranded)2021 - Present
- PEDIATRIC ADVISORY BOARD, ASTRA ZENECA/ALEXION2020 - 2022
- Pediatric Advisory Board, Celgene2016 - 2020
External Links
- Aflac Cancer Centerhttps://winshipcancer.emory.edu/bios/faculty/fangusaro-jason.html
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









